监测药物治疗后的帕金森病:rs-MRI数据的CGP分类
Towards Monitoring Parkinson's Disease Following Drug Treatment: CGP Classification of rs-MRI Data
摘要:
背景和目的:人们普遍认为,准确监测神经退行性疾病对于有效的疾病管理以及药物和治疗的提供至关重要。本研究开发了PD的自动临床监测技术,治疗后,使用EA的新应用。具体而言,研究问题是:使用EA对处方莫达非尼(通常为PD患者开具,以缓解身体疲劳)的患者的rs-fMRI数据进行准确监测能否实现PD?研究方法:这项研究开发了新的临床监测工具,使用来自对照实验的数据,其中参与者被给予莫达非尼与安慰剂,检查EA的新应用,以使用rs-fMRI数据来映射和预测参与者的功能连接。具体而言,CGP用于分类DCM分析和时间序列数据。结果进行了验证与其他两种常用的分类方法(ANN和SVM),并通过k倍交叉验证。结果:CGP的最高准确率为74.57%。此外,CGP提供了相当的性能精度相对于ANN和SVM。然而,EA使我们能够解码分类器,在理解所使用的数据输入方面,比ANN和SVM更容易。结论:这些研究结果强调了DCM分析分类和CGP作为一种新的分类技术的适用性,脑成像数据与药物监测的医学意义。此外,分类的功能磁共振成像数据的研究通常涉及统计建模技术往往是假设驱动,而EA使用数据驱动的解释性建模方法,从而产生许多好处。DCM分析对于分类是新颖的,并且是有利的,因为它提供了关于不同大脑区域之间的因果联系的信息。
英文摘要:
Background and Objective: It is commonly accepted that accurate monitoring of neurodegenerative diseases is crucial for effective disease management and delivery of medication and treatment. This research develops automatic clinical monitoring techniques for PD, following treatment, using the novel application of EAs. Specifically, the research question addressed was: Can accurate monitoring of PD be achieved using EAs on rs-fMRI data for patients prescribed Modafinil (typically prescribed for PD patients to relieve physical fatigue)? Methods: This research develops novel clinical monitoring tools using data from a controlled experiment where participants were administered Modafinil versus placebo, examining the novel application of EAs to both map and predict the functional connectivity in participants using rs-fMRI data. Specifically, CGP was used to classify DCM analysis and timeseries data. Results were validated with two other commonly used classification methods (ANN and SVM) and via k-fold cross-validation. Results: Findings revealed a maximum accuracy of 74.57% for CGP. Furthermore, CGP provided comparable performance accuracy relative to ANN and SVM. Nevertheless, EAs enable us to decode the classifier, in terms of understanding the data inputs that are used, more easily than in ANN and SVM. Conclusions: These findings underscore the applicability of both DCM analyses for classification and CGP as a novel classification technique for brain imaging data with medical implications for medication monitoring. Furthermore, classification of fMRI data for research typically involves statistical modelling techniques being often hypothesis driven, whereas EAs use data-driven explanatory modelling methods resulting in numerous benefits. DCM analysis is novel for classification and advantageous as it provides information on the causal links between different brain regions.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。